Coreline Soft, a medical artificial intelligence (AI) specialist led by CEO Kim Jin-kook, has announced that it will participate in the “KSEM 2025 Autumn Scientific Meeting of the Korean Society of Emergency Medicine”, which will take place on 30–31 October at the Swiss Grand Hotel in Seoul. At the event, the company will present its range of emergency diagnostic AI solutions.
At the conference, Coreline Soft plans to showcase its brain-hemorrhage detection and diagnostic software AVIEW NeuroCAD, alongside an Emergency AI Package that also includes its AI technologies assisting the diagnosis of aortic dissection (Aorta) and pulmonary embolism (PE).
Brain hemorrhage AI achieves over 30,000 cumulative cases… Efficiency in emergency image reads validated
AVIEW NeuroCAD is a software application that automatically identifies areas of intracranial hemorrhage in CT scans, aiding clinicians in making rapid judgments. Since its launch just one year and a half ago, the product has surpassed a cumulative usage of 30,000 cases and continues to grow rapidly. In particular, after exceeding 10,000 cases within the first nine months, it now records over 10,000 cases per quarter, becoming a key revenue source accounting for about 8-9 percent of the company’s domestic cumulative sales. Coreline Soft expects that as usage expands further, the share of sales will rise to more than 10 percent.
Emergency AI Package supports the diagnosis of severe conditions
Following AVIEW NeuroCAD, Coreline Soft has developed and obtained regulatory approval for AI diagnostic-assistance software targeting three severe conditions commonly diagnosed in emergency rooms via CT imaging: intracranial hemorrhage, aortic dissection, and pulmonary embolism. At the KSEM conference, the company will officially introduce this integrated Emergency AI Package, presenting the possibility that AI can improve both the speed and accuracy of image interpretation in emergency care settings.
Park Joon-min, Senior Vice President and Chief Product Officer (CPO) of Coreline Soft and a former emergency-medicine specialist, noted that the company’s progress reflects changes in clinical adoption. “The meaningful point is not simply that usage is increasing as a non-insured item, but that AI diagnostic technology is taking root in the actual clinical workflow,” he said. “Coreline Soft will continue to develop technologies that improve the quality of emergency medical care and protect the golden hour of critically ill patients through AI.”
